Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 05, 2022

Efficacy of Trastuzumab–Emtansine and Lapatinib After Dual HER2 Inhibition With Trastuzumab and Pertuzumab in Patients With Metastatic Breast Cancer

The Breast


Additional Info

The Breast
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
Breast 2022 Mar 11;63(2022)54-60, F Moinard-Butot, C Saint-Martin, C Pflumio, M Carton, W Jacot, PH Cottu, V Diéras, F Dalenc, A Goncalves, M Debled, A Patsouris, MA Mouret-Reynier, L Vanlemmens, M Leheurteur, G Emile, JM Ferrero, I Desmoulins, L Uwer, JC Eymard, B Cheaib, C Courtinard, T Bachelot, M Chevrot, T Petit

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading